Endologix to Collaborate With Japan Lifeline on Thoracic Endovascular Systems in Japan

 

September 11, 2017—Endologix, Inc. announced that it has signed a joint research and development agreement, as well as an exclusive distribution agreement, with Japan Lifeline Co., Ltd. (JLL) pertaining to the development and distribution of novel endovascular stent graft systems for the treatment of thoracic aortic diseases.

Under the terms of these agreements, the companies will jointly invest in the development, clinical research, and commercialization of the new thoracic systems. JLL has exclusive distribution rights to the devices in Japan, and Endologix intends to commercialize and sell the systems through its existing global sales force and distribution partners in countries other than Japan.

JLL is the exclusive distributor in Japan for Endologix products, including the AFX and AFX2 endograft systems for the treatment of abdominal aortic aneurysms. JLL will also facilitate the Japanese market launches of Endologix's Ovation and Nellix devices in the future.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.